Skip to main navigation Skip to search Skip to main content

Blood eosinophil count predicts treatment failure and hospital readmission for copd

  • Marjan Kerkhof
  • , Isha Chaudhry
  • , Ian D. Pavord
  • , Marc Miravitlles
  • , Chin Kook Rhee
  • , David M.G. Halpin
  • , Omar S. Usmani
  • , Rupert Jones
  • , Janwillem Kocks
  • , Marianna Alacqua
  • , Tamsin Morris
  • , Alan Kaplan
  • , David B. Price
  • Observational and Pragmatic Research Institute
  • University of Oxford
  • Vall d'Hebron Research Institute
  • University of Exeter
  • Imperial College London
  • University of Plymouth
  • AstraZeneca
  • Family Physician Airways Group of Canada
  • University of Aberdeen

Research output: Contribution to journalArticlepeer-review

11 Scopus citations

Abstract

We examined associations between blood eosinophil counts (BEC) and risk of treatment failure or hospital readmission following acute oral corticosteroid (OCS)-treated COPD exacerbations. We conducted studies from the Optimum Patient Care Research Database (OPCRD) (www. optimumpatientcare.org/opcrd) and Clinical Practice Research Datalink (CPRD) (www.cprd.com/home/), validated databases for medical research, with linked Hospital Episode Statistics (HES) data for ∼20 000 COPD patients aged ⩾40 years. For patients with OCS-treated COPD exacerbations treated in primary care, with BECs recorded on first day of OCS treatment (Cohort 1), we assessed treatment failure (COPD-related hospitalisations and OCS prescriptions beyond index OCS course). For patients hospitalised for COPD exacerbations, with BEC measured over an exacerbation-free period during the year prior to admission (Cohort 2), we assessed readmission rate. Cox proportional hazards regression analysis was adjusted for confounders to estimate the association between BEC and treatment outcomes. Of patients treated with OCS for COPD exacerbations in primary care (Cohort 1), 44% experienced treatment failure following single OCS courses, and 10% (255/2482) were hospitalised for ⩽6 weeks. Greater BEC was associated with reduced hospital-admission risk (hazard ratio [HR]=0.26; 95% CI: 0.12–0.56, per 100 cells·µL−1 increase). BEC increases of ⩾200 cells·µL−1 from exacerbation-free periods to exacerbations were associated with least hospitalisation risk (HR=0.32; 95% CI: 0.15–0.71) versus no BEC change. For patients hospitalised for COPD exacerbations (Cohort 2), 4-week hospital readmission was 12% (1189/10245). BEC increases during an exacerbation-free period within the past year were associated with reduced risk of short-term readmission (HR=0.78; 95% CI: 0.63–0.96). Greater BEC predicted better outcomes for patients with OCS-treated COPD exacerbations, whether community or hospital managed. Eosinopenia predicted worse outcomes.

Original languageEnglish
Article number00188-2020
Pages (from-to)1-12
Number of pages12
JournalERJ Open Research
Volume6
Issue number4
DOIs
StatePublished - 1 Oct 2020

Bibliographical note

Publisher Copyright:
© ERS 2020.

Fingerprint

Dive into the research topics of 'Blood eosinophil count predicts treatment failure and hospital readmission for copd'. Together they form a unique fingerprint.

Cite this